Aldeyra Therapeutics, Inc.
reproxalap
dry eye disease
Date
TBD
Advisory committee · Date TBD estimated
What's at stake
An FDA advisory committee reviews reproxalap for dry eye disease around Date TBD. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 8-K
verified 14h ago
“Aldeyra intends to request a Type A meeting with the FDA to understand the actions needed for approval of the reproxalap NDA.”